Recession USA 2020

European advisory group backs expanded use of Crysvita (NASDAQ:RARE)

Ultragenyx (RARE -1.3%) collaboration partner Kyowa Kirin Co., Ltd. (OTCPK:KYKOF) announces a positive opinion from the European Medicines Agency’s advisory group CHMP backing expanded labeling for Crysvita (burosumab) to include older adolescents and adults with X-linked hypophosphatemia, an inherited disorder characterized by low levels of phosphate in the blood leading to soft and weak bones (rickets). Ingesting vitamin D does not offer a benefit to sufferers.

Crysvita was conditionally approved in Europe in February 2018 for children at least one year old with radiographic evidence of bone disease and adolescents with growing skeletons.

Related posts

Controladora Vuela Compañía de Aviación, S.A.B. de C.V. reports Q3 results

Doubts remain over true scale of US jobless crisis

Delta and Alitalia are bringing back quarantine-free flights between the U.S. and Europe

Leave a Comment